Monopar Therapeutics
NASDAQ: MNPRLake Forest, US · Founded 2014 · Delaware corporation · 4 known investors
Monopar Therapeutics is a clinical-stage biotechnology company developing radiopharmaceuticals for oncology imaging and treatment of advanced solid tumors, along with ALXN1840, a late-stage investigational treatment for Wilson Disease, a rare genetic disorder. It advances its pipeline through in-house development and licensing of late-preclinical and clinical-stage therapeutics.
Founders & leadership
Monopar Therapeutics was founded in 2014 by Chandler D. Robinson.
CD
Chandler D. RobinsonFounder
CM
Christopher M. StarrExecutive
AP
Andrew P. MazarNamed on SEC filing
Board
MJ
Michael J. BrownBoard director
Investors · 4
Also in the syndicate · 2
Adage Capital Partners LPADAR1 Capital Management
Reported raises · per SEC filings
Form D private placements$2.1M disclosed across 1 of 5 rounds · 2015–2024
▶$4.5MofferedAug 2017 · BiotechnologyRule 506(b)
▶$4.5MofferedAug 2017 · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Chandler D. RobinsonExecutive Officer, Director
- Andrew P. MazarExecutive Officer, Director
- Christopher M. StarrExecutive Officer, Director
- Michael J. BrownDirector
- Raymond W. AndersonDirector
- Offering amount
- $4.5M
- Minimum investment
- $120K
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$10MofferedMar 2017 · BiotechnologyRule 506(b)
▶$10MofferedMar 2017 · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Christopher M. StarrExecutive Officer, Director
- Michael J. BrownDirector
- Chandler D. RobinsonExecutive Officer, Director
- Andrew P. MazarExecutive Officer, Director
- Offering amount
- $10M
- Minimum investment
- $120K
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$3MofferedMar 2016 · BiotechnologyRule 506(b)
▶$3MofferedMar 2016 · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael J. BrownDirector
- Chandler D. RobinsonExecutive Officer, Director
- Christopher M. StarrExecutive Officer, Director
- Andrew P. MazarExecutive Officer, Director
- Offering amount
- $3M
- Minimum investment
- $250.2K
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$2.1MraisedJun 2015 · 8 investors · BiotechnologyRule 506(b)
▶$2.1MraisedJun 2015 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Chandler D. RobinsonExecutive Officer, Director, Promoter
- Christopher M. StarrExecutive Officer, Director
- Andrew P. MazarExecutive Officer, Director
- Michael J. BrownDirector
- Offering amount
- $6M
- Amount sold
- $2.1M
- Minimum investment
- $250K
- Proceeds to insiders
- $1.4M
- First sale
- Jun 2015
- Incorporated
- Limited Liability Company, Delaware, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlapPerplexity14 shared keywordsAn AI-powered answer engine providing accurate, trusted, and real-time answers to questions.
StockTwits13 shared keywordsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.
Robinhood13 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Bioworld13 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Companies competing with Monopar Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Monopar Therapeutics do?
- Monopar Therapeutics is a clinical-stage biotechnology company developing radiopharmaceuticals for oncology imaging and treatment of advanced solid tumors, along with ALXN1840, a late-stage investigational treatment for Wilson Disease, a rare genetic disorder. It advances its pipeline through in-house development and licensing of late-preclinical and clinical-stage therapeutics.
- Who founded Monopar Therapeutics?
- Monopar Therapeutics was founded by Chandler D. Robinson in 2014.
- Who are Monopar Therapeutics's investors?
- Monopar Therapeutics's investors include Janus Henderson Investors, RA Capital.
- How much funding has Monopar Therapeutics raised?
- Monopar Therapeutics has disclosed $2.1M raised across 1 of its 5 known rounds.
- Where is Monopar Therapeutics headquartered?
- Monopar Therapeutics is headquartered in Lake Forest, US.